Robert E. W. Hancock


Robert Ernest William Hancock is a Canadian microbiologist and University of British Columbia Killam Professor of Microbiology and Immunology, an Associate Faculty Member of the Wellcome Trust Sanger Institute, and a Canada Research Chair in Health and Genomics.
Over his career he has published more than 800 papers and reviews, has 72 patents awarded, and is an ISI highly cited author in Microbiology with more than 113,000 citations and an h-index of 168. He has won several awards and is an Officer of the Order of Canada. He is a co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset Biotherapeutics, and the Centre for Drug Research and Development. He serves as a member of the Scientific Advisory Board for Qu Biologics.
WWW cmdr.ubc.ca/bobh𝕏 thehancocklab

Education

Hancock received his BSc and PhD in Microbiology from the University of Adelaide, where he studied bacteriophage receptors. He did his post-doctoral work at the University of Tübingen in Germany, where he studied the E. coli outer membrane, followed by a research year at the University of California, Berkeley. At Berkeley, he began his work on Pseudomonas aeruginosa and porins proteins that form channels in membranes. While at UBC he came up with the self-promoted uptake theory, the idea that antibiotics promote their own uptake across the cell membrane.

Research

Hancock began studying antibiotic resistance mechanisms in Pseudomonas aeruginosa, which eventually led to his involvement in sequencing the genome of Pseudomonas, only the 4th bacterial genome to be sequenced. Hancock's research identified new mechanisms of antibiotic resistance especially dependent on lifestyle adaptations in Pseudomonas, and found new therapeutics for treating antibiotic resistant pathogens. This then led to investigating small cationic peptides from nature, originally termed cationic antimicrobial peptides, but eventually "host defence peptides". Hancock became one of the first and most prominent advocates that the major function of these peptides was as modulators of the immune system. To understand the role of these peptides as modulators of the immune system he developed InnateDB, NetworkAnalyst and MetaBridge as tools to enable systems/network biology studies and insights.
Currently Hancock and his lab’s research interests include small cationic peptides as novel antimicrobials, broad-spectrum anti-biofilm agents, and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections and inflammation, the systems biology of innate immunity, inflammatory diseases and Pseudomonas aeruginosa, and antibiotic uptake and resistance.

Other work

Canadian Anti-infective Innovation Network (CAIN)

Hancock and Gerry Wright formed the Canadian Anti-infective Innovation Network in 2017. CAIN was formed with the purpose of leveraging innovative approaches and expertise to solve the expanding health crisis caused by Antimicrobial Resistance infections. In less than a year CAIN grew to over 90 members from across Canada.

Centre for Microbial Diseases and Immunity Research (CMDR)

Hancock is the director of the Centre for Microbial Diseases and Immunity Research a multi-faculty, multi-department consortium of world class microbial diseases and immunology researchers located at the University of British Columbia.

Awards and honours

Ventures

Hancock co-founded the following companies: